Cargando…

Banting memorial lecture 2022: ‘Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime’

Nonalcoholic fatty liver disease (NAFLD) was first described in the 1980s, but in the 21st century, NAFLD has become a very common condition. The explanation for this relatively recent problem is in large part due to the recent epidemic of obesity and type 2 diabetes (T2DM) increasing the risk of NA...

Descripción completa

Detalles Bibliográficos
Autor principal:	Byrne, Christopher D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546361/ https://www.ncbi.nlm.nih.gov/pubmed/35790023 http://dx.doi.org/10.1111/dme.14912

Ejemplares similares

Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes
por: Taylor, R
Publicado: (2013)

Banting Lecture 2011: Hyperinsulinemia: Cause or Consequence?
por: Corkey, Barbara E.
Publicado: (2012)

Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes
por: Eisenbarth, George S.
Publicado: (2010)

Lipoprotein metabolism in nonalcoholic fatty liver disease
por: Jiang, Zhenghui Gordon, et al.
Publicado: (2013)

Innate immunity and nonalcoholic fatty liver disease
por: Kountouras, Jannis, et al.
Publicado: (2023)

The Multifaceted Roles of Adipose Tissue—Therapeutic Targets for Diabetes and Beyond: The 2015 Banting Lecture
por: Scherer, Philipp E.
Publicado: (2016)

Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture
por: Accili, Domenico
Publicado: (2018)

K(ATP) Channels and the Metabolic Regulation of Insulin Secretion in Health and Disease: The 2022 Banting Medal for Scientific Achievement Award Lecture
por: Ashcroft, Frances M.
Publicado: (2023)

Banting Lecture 2012: Regulation of Adipogenesis: Toward New Therapeutics for Metabolic Disease
por: Spiegelman, Bruce M.
Publicado: (2013)

Adipose Tissue, Inter-Organ Communication, and the Path to Type 2 Diabetes: The 2016 Banting Medal for Scientific Achievement Lecture
por: Kahn, Barbara B.
Publicado: (2019)

Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture
por: Holst, Jens Juul
Publicado: (2021)

A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease
por: Manka, Paul P., et al.
Publicado: (2021)

Banting in India, with Remarks on Diet
Publicado: (1885)

A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture
por: Ferrannini, Ele
Publicado: (2021)

How to Get Thin; or Banting in India
Publicado: (1878)

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
por: Lorenzatti, Alberto J., et al.
Publicado: (2021)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Recognition of Children’s Learning in Educational Research, Policy and Practice: Herbison Invited Lecture, NZARE Annual Conference 2022
por: O’Neill, John
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2018)

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
por: Rosenson, Robert S., et al.
Publicado: (2019)

Following in Banting’s footsteps or straying from the path? Observations from contemporary diabetes innovation
por: Leadley, Connor, et al.
Publicado: (2023)

“Treasure Your Exceptions”—Studying Human Extreme Phenotypes to Illuminate Metabolic Health and Disease: The 2019 Banting Medal for Scientific Achievement Lecture
por: O’Rahilly, Stephen
Publicado: (2021)

The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Frederick Banting's observations leading to the potential for islet neogenesis without transplantation
por: Levetan, Claresa
Publicado: (2021)

Partners in Crime: Beta-Cells and Autoimmune Responses Complicit in Type 1 Diabetes Pathogenesis
por: Toren, Eliana, et al.
Publicado: (2021)

Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Mutant p53 partners in crime
por: Kim, Michael P, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
por: Rhee, Eun-Jung
Publicado: (2019)

Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist
por: Khandelwal, Reshu, et al.
Publicado: (2022)

Strategies, debates, and adversarial collaboration in working memory: The 51st Bartlett Lecture
por: Logie, Robert H
Publicado: (2023)

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dai, Chia-Yen, et al.
Publicado: (2022)

Elizabeth Usher Memorial Lecture: Language is literacy is language - Positioning speech-language pathology in education policy, practice, paradigms and polemics
por: Snow, Pamela C.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
por: Huh, Ji Hye
Publicado: (2022)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
por: Seo, Da Hea, et al.
Publicado: (2022)

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
por: Alkhouri, Naim, et al.
Publicado: (2018)

Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus
por: Cho, Hyo Jung, et al.
Publicado: (2019)

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
por: Portillo-Sanchez, Paola, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vpv8lkovle6kvuehck5df9co4j